Razi Vaccine & Serum Research Institute

rvsri.ac.ir

Razi Vaccine and Serum Research Institute is the reference institution for a vast range of human and animal diseases drugs in middle east. In addition, the institute utilizes modern facilities to cope with WHO demands. Furthermore, it is one of the oldest pharmaceuticals all around the world, whilst the cutting edge and pioneer in the sense of research and invention in the region.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

THERMO FISHER SCIENTIFIC HIGHLIGHTS GROWING CAPACITY FOR BIOLOGICS, CELL AND GENE THERAPY PRODUCTION DURING BIO 2020

PR Newswire | June 08, 2020

news image

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the BIO International Convention, June 8-12, now a virtual event at www.bio.org/events/bio-digital."We can now provide an uninterrupted path from development to commercialization for biopharma companies, small to large, in geographies worldwide and across vaccine...

Read More

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

news image

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

news image

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More

CELL AND GENE THERAPY

SARTORIUS STEDIM BIOTECH STRENGTHENS ITS PRODUCT PORTFOLIO FOR CELL AND GENE THERAPIES BY ACQUIRING A MAJORITY STAKE IN CELLGENIX

Sartorius | July 05, 2021

news image

Sartorius Stedim Biotech, a leading international biopharmaceutical partner, has acquired a majority stake in CellGenix GmbH, a reagent manufacturer. The company, headquartered in Freiburg, Germany, and with a sales subsidiary near the biotechnology center in Boston, Massachusetts, USA, manufactures and distributes cell culture components in GMP grade for the manufacture of cell and gene therapy products. Sartorius Stedim Biotech originally purchased 51% of this company, which was...

Read More
news image

THERMO FISHER SCIENTIFIC HIGHLIGHTS GROWING CAPACITY FOR BIOLOGICS, CELL AND GENE THERAPY PRODUCTION DURING BIO 2020

PR Newswire | June 08, 2020

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the BIO International Convention, June 8-12, now a virtual event at www.bio.org/events/bio-digital."We can now provide an uninterrupted path from development to commercialization for biopharma companies, small to large, in geographies worldwide and across vaccine...

Read More
news image

INDUSTRIAL IMPACT

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More
news image

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More
news image

CELL AND GENE THERAPY

SARTORIUS STEDIM BIOTECH STRENGTHENS ITS PRODUCT PORTFOLIO FOR CELL AND GENE THERAPIES BY ACQUIRING A MAJORITY STAKE IN CELLGENIX

Sartorius | July 05, 2021

Sartorius Stedim Biotech, a leading international biopharmaceutical partner, has acquired a majority stake in CellGenix GmbH, a reagent manufacturer. The company, headquartered in Freiburg, Germany, and with a sales subsidiary near the biotechnology center in Boston, Massachusetts, USA, manufactures and distributes cell culture components in GMP grade for the manufacture of cell and gene therapy products. Sartorius Stedim Biotech originally purchased 51% of this company, which was...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us